PPARγ and C/EBPα enable adipocyte differentiation upon inhibition of histone methyltransferase PRC2 in malignant tumors
Journal of Biological Chemistry · 2024
DOI: 10.1016/j.jbc.2024.107765 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2024. Verfasst von Jiaqi Zhao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Gene Editing Center, School of Life Science and Technology, ShanghaiTech University, Shanghai, China. Hauptthemen laut MEDLINE: PPAR gamma, Adipocytes, Cell Differentiation, CCAAT-Enhancer-Binding Protein-alpha. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Public Security of the People's Republic of China, Ministry of Science and Technology of the People's Republic of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Loss of terminal differentiation is a hallmark of cancer and offers a potential mechanism for differentiation therapy. Polycomb repressive complex 2 (PRC2) serves as the methyltransferase for K27 of histone H3 that is crucial in development. While PRC2 inhibitors show promise in treating various cancers, the underlying mechanisms remain incompletely understood. Here, we demonstrated that the inhibition or depletion of PRC2 enhanced adipocyte differentiation in malignant rhabdoid tumors and mesenchymal stem cells, through upregulation of peroxisome proliferator-activated receptor gamma (PPARG) and CEBPA. Mechanistically, PRC2 directly represses their transcription through H3K27 methylation, as both genes exhibit a bivalent state in mesenchymal stem cells. KO of PPARG compromised C/EBPα expression and impeded the PRC2 inhibitor-induced differentiation into adipocytes. Furthermore, the combination of the PPARγ agonist rosiglitazone and the PRC2 inhibitor MAK683 exhibited a higher inhibition on Ki67 positivity in tumor xenograft compared to MAK683 alone. High CEBPA, PLIN1, and FABP4 levels positively correlated with favorable prognosis in sarcoma patients in The Cancer Genome Atlas cohort. Together, these findings unveil an epigenetic regulatory mechanism for PPARG and highlight the essential role of PPARγ and C/EBPα in the adipocyte differentiation of malignant rhabdoid tumors and sarcomas with a potential clinical implication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gene Editing Center, School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
- China Novartis Institutes for BioMedical Research, Shanghai, China.
- Gene Editing Center, School of Life Science and Technology, ShanghaiTech University, Shanghai, China. Electronic address: qiwei@shanghaitech.edu.cn.
Förderung
- Ministry of Public Security of the People's Republic of China
- Ministry of Science and Technology of the People's Republic of China
- National Natural Science Foundation of China
- ShanghaiTech University
Zitieren
APA
Zhao, J., Qian, H., An, Y., Chu, L., Tan, D., Qin, C., Sun, Q., Wang, Y., & Qi, W. (2024). PPARγ and C/EBPα enable adipocyte differentiation upon inhibition of histone methyltransferase PRC2 in malignant tumors. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2024.107765
Vancouver
Zhao J, Qian H, An Y, Chu L, Tan D, Qin C, et al. PPARγ and C/EBPα enable adipocyte differentiation upon inhibition of histone methyltransferase PRC2 in malignant tumors. Journal of Biological Chemistry. 2024. doi:10.1016/j.jbc.2024.107765
BibTeX
@article{Zhao2024,
author = {Zhao, Jiaqi and Qian, Hui and An, Yang and Chu, Liping and Tan, Dongxia and Qin, Chenyang and Sun, Qianying and Wang, Yunpeng and Qi, Wei},
title = {PPARγ and C/EBPα enable adipocyte differentiation upon inhibition of histone methyltransferase PRC2 in malignant tumors},
journal = {Journal of Biological Chemistry},
year = {2024},
doi = {10.1016/j.jbc.2024.107765}
}
EUVIMED